Get startedLog in
    Picture of Eli Lilly and logo

    LLY — Eli Lilly and News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Formulation Product By 2026 End

    Picture of Eli Lilly and logoEli Lilly and
    30/09/2026 15:15
    BRIEF-Eli Lilly Plans To Initiate Phase 3 Studies Of Eloratzp Co-Formulation Product By 2026 End
    Sept 30 (Reuters) - Eli Lilly and Company LLY.N:
    • ELI LILLY: AT 48 WEEKS, ALL COMBINATIONS OF ELORATZP MET PRIMARY & SECONDARY ENDPOINTS
    • ELI LILLY: PLANS TO INITIATE PHASE 3 STUDIES OF ELORATZP CO-FORMULATION PRODUCT BY 2026 END USING OPTIMIZED ESCALATION SCHEDULE
    • ELI LILLY: PARTICIPANTS TAKING ELORATZP LOST UP TO AVERAGE OF 54.1 LBS (23.3%) VERSUS. 34.4 LBS (14.8%) WITH TIRZEPATIDE 15 MG
    • ELI LILLY: PARTICIPANTS TAKING ELORATZP LOWERED THEIR A1C BY UP TO AVERAGE OF 2.9% VERSUS. 2.4% WITH TIRZEPATIDE 15 MG
    Source text: [ID:]
    Further company coverage: LLY.N

     (Reporting by Zakia Mariyam)
     ((Zakia.Mariyam@thomsonreuters.com;))

    Recent news on Eli Lilly and

    See all news